Phylogica expands peptide drug conjugates pact with Janssen
Australian firm has received an undisclosed payment to fund additional research
Phylogica, an Australian peptide drug discovery company, has extended its collaboration with Janssen Biotech to develop new peptide drug conjugates derived from Phylogica’s Phylomer drug discovery platform.
Perth-based Phylogica has received an undisclosed payment to fund additional research connected with the collaboration.
The agreement with Janssen was originally signed in December 2011. This expansion follows the identification of Phylomers that specifically target the tissue-type of interest and internalise a payload within the cell. This screening phase was conducted using Phylogica’s second-generation Phylomer libraries and newly developed technology. Phylogica has recently filed a patent application on this platform enhancement.
The two firms will now explore the ability of the Phylomer conjugates to function within the cell. This is anticipated to take about 6 months to complete.
